New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
16:25 EDTBBY, RIGL, GE, ARIA, PAY, QUAD, ADBEOn The Fly: Closing Wrap
Stocks on Wall Street finished lower after the averages sat just below the flat line for much of the session. Stocks moved lower during the final ninety minutes of trading, leaving each of the major averages down on the week... ECONOMIC EVENTS: In the U.S., a report showed consumer prices declined 0.3% in November, mainly because of falling gasoline costs. When food and energy are removed from the equation, "core" prices increased 0.1%, versus expectations for them to rise 0.2%. Markit's preliminary manufacturing PMI improved to 54.2 in December, versus the 52.8 final reading for November. Industrial production beat expectations with a 1.1% increase in November, versus expectations for a rise of 0.3%. Industrial production capacity utilization rose to 78.4%, which was a bit more than an expected move up to 78.0%. In China, Markit's flash China PMI rose to a 14-month high reading of 50.9, beating expectations for a 50.8 reading. In Europe, Germany's flash PMI hit an 8-month high with a 50.2 reading... COMPANY NEWS: General Electric (GE) boosted its dividend by 12% to 19c per share and increased its existing share repurchase authorization by $10B... Among companies reporting earnings last night, Adobe (ADBE) shares rose $2.05, or 5.77%, to $37.58, while shares of VeriFone (PAY) declined $3.63, or 10.92%, to $29.60... MAJOR MOVERS: Among the notable gainers was Rigel Pharmaceuticals (RIGL), up $1.01, or 18.33%, to $6.52 after Leerink called the recent pullback a "temporary dislocation" and maintained an Outperform rating in the name. Also higher were shares of Quad/Graphics (QUAD), up $2.40, or 14.36%, to $19.11 after the company increased its quarterly dividend by 20% and declared a $2.00 per share special dividend. Among noteworthy losers was Aria Pharmaceuticals (ARIA), down $4.95, or 20.73%, to $18.93 after announcing that its leukemia treatment was approved by the FDA, though the regulator required that the drug include a "Boxed Warning." Shares of Best Buy (BBY) also slid $2.07, or 14.66%, to $12.05 after the company's board extended the deadline for founder Richard Schulze to deliver a potential buy-out bid... INDICES: The Dow was down 35.71, or 0.27%, to 13,135.01; the Nasdaq was down 20.83, or 0.70%, to 2,971.33; the S&P 500 was down 5.87, or 0.41%, to 1,413.58.
News For GE;ADBE;PAY;RIGL;QUAD;ARIA;BBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 24, 2015
18:02 EDTGEGeneral Electric director purchases $20M of company stock
According to regulatory filings, GE director William G. Beattie purchased 800,000 shares of GE for $20,096,000 on February 18 and 19.
10:12 EDTARIAOptions with increasing implied volatility: LO ARIA OWW
February 23, 2015
17:08 EDTQUADQuad/Graphics sees FY15 revenue $4.8B-$5B, consensus $4.83B
Subscribe for More Information
17:07 EDTQUADQuad/Graphics reports Q4 adjusted EPS 96c, consensus 94c
Reports Q4 revenue $1.42B, consensus $1.4B.
12:21 EDTRIGLOn The Fly: Midday Wrap
Subscribe for More Information
12:07 EDTGEEU opens probe in GE's proposed acquisition of Alstom's energy business
The European Commission has opened an in-depth investigation to assess whether General Electric's (GE) proposed acquisition of the Thermal Power, Renewable Power & Grid businesses of Alstom (ALSMY) is in line with the EU Merger Regulation. The Commission’s preliminary investigation indicates potential competition concerns in the market for heavy-duty gas turbines which are mainly used in gas-fired power plants. The transaction would bring together the activities of GE, the world's largest manufacturer of heavy-duty gas turbines, with those of Alstom, eliminating one of the three main global competitors to GE in this market. The opening of an in-depth inquiry does not prejudge the final result of the investigation. The Commission now has 90 working days, until 8 July, to take a final decision. Reference Link
10:45 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
09:25 EDTRIGLOn The Fly: Pre-market Movers
Subscribe for More Information
08:15 EDTRIGLRigel Pharmaceuticals and Bristol-Myers announces R&D collaboration agreement
Rigel Pharmaceuticals (RIGL) and Bristol-Myers (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo and Yervoy. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:06 EDTRIGLBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system’s activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel’s TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:00 EDTADBEAdobe shares recommended at Rosenblatt
Rosenblatt believes Adobe continues to execute and will report Q1 earnings and revenues slightly ahead of consensus estimates of 40c/1.09B and for new sub adds and Marketing Cloud billing to be above expectations.
05:46 EDTARIAStocks with implied volatility movement; ARIA CYBR
Subscribe for More Information
February 20, 2015
08:26 EDTGEArc Logistics to acquire all membership interests Joliet Bulk for $216M
Subscribe for More Information
06:35 EDTARIASarissa Capital seeks retirement of ARIAD CEO, board seats
Sarissa Capital disclosed in a regulatory filing that it has been in negotiations with members of ARIAD's board in an attempt to avoid a potential proxy contest. Sarissa said it indicated its belief that the board undertake measures to effect and facilitate the imminent retirement of Harvey Berger as CEO and that any settlement of a potential proxy contest must include the CEO’s retirement. It added that no settlement has been reached. Sarissa believes the board "as currently constructed is not up to the task of providing the stewardship necessary to optimally navigate" the company. On February 19, Sarissa notified ARIAD that it intends to appear at the company's 2015 annual meeting of stockholders to nominate and seek to elect Richard Mulligan, Ph.D. and Anna Protopapas to the eight member staggered board of directors. Sarissa intends to seek to unseat Harvey Berger, ARIAD's Chairman and CEO, and Wayne Wilson, the lead independent director, with its two nominees. Sarissa added that it is "extremely concerned" with the conduct of certain members of the board, "particularly with respect to compensation, governance and financial matters." The hedge fund said it may ultimately initiate court proceedings to seek to remove one or more directors for cause based on potential breaches of their fiduciary duties. Sarissa Capital has a 6.9% stake in ARIAD.
February 19, 2015
07:39 EDTARIAARIAD expects to file IND application for AP32788 this year
ARIAD says "We expect to file an investigational new drug application for AP32788 this year and to begin a Phase 1/2 proof-of-concept trial in 2016. This will be our third IND filing of an internally discovered oncology development candidate in the past eight years." The company also says "We anticipate presenting updates from the ongoing Phase 1/2 clinical trial of brigatinib at the 2015 European Lung Cancer Conference and the American Society of Clinical Oncology meetings later this year. Additionally, we expect to present preliminary data from the brigatinib ALTA trial in the second half of 2015."
07:38 EDTARIAARIAD sees FY15 net product revenues from sales of Iclusig $130M-$140M
Net product revenues from sales of Iclusig are expected to be in the range of $130M-$140M. This guidance includes sales of Iclusig in the U.S., Europe, and other select countries where ARIAD has distributorships in place. R&D expenses are expected to be in the range of $185M-$195M, reflecting increased development activities for Iclusig, brigatinib, and AP32788, as well as ongoing discovery research efforts. Expenses related to Iclusig represent approximately 50% of total R&D expenses and include the three new planned trials to begin this year, as well as all ongoing trials. Expenses related to brigatinib represent approximately 35% of total R&D expenses and include the two ongoing trials and NDA-enabling pre-clinical studies.
07:37 EDTARIAARIAD reports Q4 EPS (3c), consensus (20c)
Subscribe for More Information
February 18, 2015
11:14 EDTGEGE, Alstom deal likely to face intense EU scrutiny, Reuters says
General Electric's (GE) deal for Alstom's (ALSMY) power equipment business is likely to face an intense EU antitrust investigation, says Reuters, citing people familiar with the matter. Reference Link
09:32 EDTBBYComarco files patent suit against Best Buy
Subscribe for More Information
07:07 EDTGEBarclays to hold a conference
Industrial Select Conference is being held in Miami on February 18-19.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use